Arginine derivatives such as ADMA and SDMA serve as biomarkers of cerebrovascular risk and ischemic stroke, whereas homoarginine is inversely associated with adverse events and mortality.
Arginine derivatives such as ADMA and SDMA serve as biomarkers for cerebrovascular risk, while homoarginine may offer protective effects in ischemic stroke.
The amino acid L-arginine serves as substrate for the nitric oxide synthase which is crucial in vascular function and disease. Derivatives of arginine, such as asymmetric (ADMA) and symmetric dimethylarginine (SDMA), are regarded as markers of endothelial dysfunction and have been implicated in vascular disorders. While there is a variety of studies consolidating ADMA as biomarker of cerebrovascular risk, morbidity and mortality, SDMA is currently emerging as an interesting metabolite with distinct characteristics in ischemic stroke. In contrast to dimethylarginines, homoarginine is inversely associated with adverse events and mortality in cerebrovascular diseases and might constitute a modifiable protective risk factor. This review aims to provide an overview of the current evidence for the pathophysiological role of arginine derivatives in cerebrovascular ischemic diseases. We discuss the complex mechanisms of arginine metabolism in health and disease and its potential clinical implications in diverse aspects of ischemic stroke.
Große et al. (Thu,) conducted a review in Cerebrovascular ischemic diseases. Arginine derivatives (ADMA, SDMA, homoarginine) was evaluated. Arginine derivatives such as ADMA and SDMA serve as biomarkers of cerebrovascular risk and ischemic stroke, whereas homoarginine is inversely associated with adverse events and mortality.